Research Index
Davunetide (NAP/AL-108) Research Index
PSI surfaces 50 peer-reviewed studies on Davunetide (NAP/AL-108), prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
NAP peptide modulated proteome profiling of rat brain cortex under hypobaric hypoxia.
Sharma NK, Bhargava K
Respir Physiol Neurobiol·2026·Animal·PubMed →
Activity-dependent neuroprotective protein (ADNP) derived peptide NAP prevents musculoskeletal abnormalities in ovariectomized mice.
Guz LS, Galushkin A, Gozes I
Front Neurosci·2026·Animal·PubMed →
Complement C3 inhibitory peptide AMY-101 ameliorates brain injury in a mouse model of NMOSD.
Zhu W, He F, Meng F et al.
Ann Med·2026·Animal·Neuroprotection·PubMed →
Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.
Shapira G, Blatt J, Guz LS et al.
Mol Psychiatry·2026·Animal·PubMed →
Aging ADNP syndrome mice exhibit mutation/sex-dependent disruption of motor behavior and circadian rhythmicity.
Galushkin A, Giladi E, Gozes I
Neurobiol Dis·2026·Animal·Longevity·PubMed →
Planimetric and Linear MRI Markers for Progressive Supranuclear Palsy Classification: A Large Multicohort International Study.
Quattrone A, Bianco MG, Vescio B et al.
Radiology·2026·Animal·PubMed →
Activity dependent neuroprotective protein mediates the protective effects against VEGF-induced corneal barrier disruption in diabetes.
Maugeri G, D'Amico AG, Palmeri N et al.
Peptides·2026·Animal·PubMed →
Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.
Schaak A, Walker M, Worden B et al.
Epilepsy Res·2026·Animal·PubMed →
Drosophila wing is a high-throughput and versatile screening tool for Tau-mediated disease mechanisms and drug discovery.
Ramirez-Moreno M, Cooper AS, Lian T et al.
Dis Model Mech·2026·Animal·Neuroprotection·PubMed →
Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration.
García-Castro J, VandeVrede L, Donohue MC et al.
J Prev Alzheimers Dis·2026·Animal·PubMed →
Davunetide promotes structural and functional recovery of the injured spinal cord by promoting autophagy.
Chen Y, Liu R, Cai W et al.
Neural Regen Res·2026·Animal·PubMed →
Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).
Gozes I, Blatt J, Guz LS
Transl Psychiatry·2025·Human·Neuroprotection·PubMed →
Brain Networks Route Neurodegeneration Patterns in Patients with Progressive Supranuclear Palsy.
Palleis C, Quattrone A, Dehsarvi A et al.
Mov Disord·2025·Human·PubMed →
The ADNP-Mediated Transcriptome Response to Ketamine Impairs the Cytoskeletal Protein Axis.
D'Incal CP, Mateiu L, De Man K et al.
J Mol Neurosci·2025·Animal·PubMed →
Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.
Quattrone A, Franzmeier N, Huppertz HJ et al.
Mov Disord·2025·Animal·PubMed →
Editorial: A Child with ADNP Syndrome: A Case Study of Symptoms, Diagnostic Process and Innovative Behavioral Intervention Modes.
Holec M, Gozes I
J Mol Neurosci·2025·Animal·PubMed →
A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.
Dam T, Yang L, Gillis C et al.
Nat Commun·2025·Animal·PubMed →
Microtubule-Targeting NAP Peptide-Ru(II)-polypyridyl Conjugate As a Bimodal Therapeutic Agent for Triple Negative Breast Carcinoma.
Chatterjee A, Sarkar S, Bhattacharjee S et al.
J Am Chem Soc·2025·Animal·PubMed →
ADNP is essential for sex-dependent hippocampal neurogenesis, through male unfolded protein response and female mitochondrial gene regulation.
Shapira G, Karmon G, Hacohen-Kleiman G et al.
Mol Psychiatry·2025·Animal·Neuroprotection·PubMed →
Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic-ischaemic encephalopathy.
Landucci E, Mango D, Carloni S et al.
Br J Pharmacol·2025·Animal·Neuroprotection·PubMed →
Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease.
Gozes I, Blatt J, Lobyntseva A
Transl Psychiatry·2024·Human·PubMed →
Concomitant Medications for Progressive Supranuclear Palsy: A Secondary Analysis of a Randomized Clinical Trial.
Iyer JM, Gunzler D, Lang AE et al.
JAMA Neurol·2024·Human·PubMed →
Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.
Kraskovskaya N, Linkova N, Sakhenberg E et al.
Int J Mol Sci·2024·Animal·Tissue Remodeling, Neuroprotection, Longevity·PubMed →
Transcriptomic alterations in APP/PS1 mice astrocytes lead to early postnatal axon initial segment structural changes.
Benitez MJ, Retana D, Ordoñez-Gutiérrez L et al.
Cell Mol Life Sci·2024·Animal·Neuroprotection·PubMed →
Sex-Specific ADNP/NAP (Davunetide) Regulation of Cocaine-Induced Plasticity.
Toren Y, Ziv Y, Sragovich S et al.
J Mol Neurosci·2024·Animal·PubMed →
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Quattrone A, Franzmeier N, Huppertz HJ et al.
Mov Disord·2024·Animal·PubMed →
Integrated ribosome and proteome analyses reveal insights into sevoflurane-induced long-term social behavior and cognitive dysfunctions through ADNP inhibition in neonatal mice.
Liang LR, Liu B, Cao SH et al.
Zool Res·2024·Animal·PubMed →
ADNP dysregulates methylation and mitochondrial gene expression in the cerebellum of a Helsmoortel-Van der Aa syndrome autopsy case.
D'Incal C, Van Dijck A, Ibrahim J et al.
Acta Neuropathol Commun·2024·Animal·PubMed →
Longitudinal Genotype-Phenotype (Vineland Questionnaire) Characterization of 15 ADNP Syndrome Cases Highlights Mutated Protein Length and Structural Characteristics Correlation with Communicative Abilities Accentuated in Males.
Levine J, Lobyntseva A, Shazman S et al.
J Mol Neurosci·2024·Animal·PubMed →
Tau, ADNP, and sex.
Gozes I
Cytoskeleton (Hoboken)·2024·Animal·PubMed →
Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.
Gozes I, Shapira G, Lobyntseva A et al.
Transl Psychiatry·2023·Animal·PubMed →
NAP (Davunetide): The Neuroprotective ADNP Drug Candidate Penetrates Cell Nuclei Explaining Pleiotropic Mechanisms.
Ganaiem M, Gildor ND, Shazman S et al.
Cells·2023·Animal·Neuroprotection·PubMed →
A novel genomic mutation in ADNP leading to intellectual disability.
Gozes I
Eur J Hum Genet·2023·Animal·PubMed →
A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome.
Gozes I, Shazman S
Eur J Neurosci·2023·Animal·PubMed →
Nanoscopy and an extended lateral approach can improve the management of latero-central segments in tibial plateau fractures: a cadaveric study.
Behrendt P, Berninger MT, Thürig G et al.
Eur J Trauma Emerg Surg·2023·Animal·PubMed →
Distinct Impairments Characterizing Different ADNP Mutants Reveal Aberrant Cytoplasmic-Nuclear Crosstalk.
Ganaiem M, Karmon G, Ivashko-Pachima Y et al.
Cells·2022·Animal·PubMed →
Cu and Zn Interactions with Peptides Revealed by High-Resolution Mass Spectrometry.
Iavorschi M, Lupăescu AV, Darie-Ion L et al.
Pharmaceuticals (Basel)·2022·Animal·PubMed →
Rational Discovery of Microtubule-Stabilizing Peptides.
Úsuga-Acevedo B, García Y, Díaz CF et al.
J Chem Inf Model·2022·Animal·PubMed →
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
VandeVrede L, Dale ML, Fields S et al.
Mov Disord Clin Pract·2020·Human·PubMed →
An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.
Çakici N, van Beveren NJM, Judge-Hundal G et al.
Psychol Med·2019·Human·PubMed →
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.
Brittain C, McCarthy A, Irizarry MC et al.
Parkinsonism Relat Disord·2019·Human·Neuroprotection·PubMed →
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
Rojas JC, Bang J, Lobach IV et al.
Neurology·2018·Human·PubMed →
Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.
Höglinger GU, Schöpe J, Stamelou M et al.
Mov Disord·2017·Human·PubMed →
Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
Hewer S, Varley S, Boxer AL et al.
Mov Disord·2016·Human·PubMed →
Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.
Tsai RM, Lobach I, Bang J et al.
Parkinsonism Relat Disord·2016·Human·PubMed →
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Boxer AL, Lang AE, Grossman M et al.
Lancet Neurol·2014·Human·PubMed →
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.
Sommer IE, van Westrhenen R, Begemann MJ et al.
Schizophr Bull·2014·Human·PubMed →
A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.
Morimoto BH, Schmechel D, Hirman J et al.
Dement Geriatr Cogn Disord·2013·Human·Cognitive Enhancement·PubMed →
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
Jarskog LF, Dong Z, Kangarlu A et al.
Neuropsychopharmacology·2013·Human·Cognitive Enhancement·PubMed →
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC, Buchanan RW, Keefe RS et al.
Schizophr Res·2012·Human·Neuroprotection·PubMed →